Back to results
US 12,415,834 B2Granted
GhR-binding peptide and composition comprising same
AssigneePeptiDream Inc.
InventorsTatsuya Tomiyama, Haruaki Kurasaki, Katsuma Matsui, Yoshiaki Masuda, Masataka Umitsu
Life of this patent
Estimating the term…
Abstract
The present technology generally relates to peptides that bind to the growth hormone receptor (GhR), to peptides that bind to the GhR and have antagonistic activity, and to compositions comprising such peptides.
Claims17
A peptide or a salt thereof consisting of the following amino acid sequence:
- (SEQ ID NO:
- 1)
- X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13
- wherein:
- X1 is an amino acid having an aromatic ring;
- X2 is N-methyl-L-lysine (MeK);
- X3 and X4 are each valine;
- X5 is serine;
- X6 is asparagine;
- X7 is tryptophan, 1-(carboxymethyl)-L-tryptophan (W1aa), 5-Methoxy-L-tryptophan (W5OMe), or 5-Hydroxy-L-Tryptophan (W5H);
- X8 is phenylalanine, 4-Carboxy-L-Phenylalanine (F4COO));
- X9 is lysine, N6-carbamimidoyl-L-lysine (Har), N6-(4-(carboxymethyl) piperazine-1-carbonyl)-L-lysine (KCOpipzaa), N-Methyl-L-Lysine (MeK), (S)-2,6-diamino-6-oxohexanoic acid (Hgn), (s)-2-aminoheptanic acid (Ahp), or arginine;
- X10 is 5-hydroxy-L-tryptophan (W5H);
- X11 is alpha-methyl alanine (Aib) or 4-amino-1-(carboxymethyl) piperidine-4-carboxylic acid (A4pipaa);
- X12 is valine;
- and
- X13 is cysteine;
- and
- wherein the peptide or the salt thereof comprises none, one, two or three conservative amino acid substitution, and wherein the peptide or the salt thereof has avidity for a growth hormone receptor (GhR).
16 more elements
Dependencies are inferred from the claim text.